Plain-English translation of NCT07275606 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a medication called cabotegravir to see if it is safe and effective at preventing HIV infection in newborns whose mothers have HIV. Researchers want to understand how the body processes this medication and whether it works well as a prevention tool. The study will test both liquid and injectable forms of the treatment in different groups of babies.
Newborns born to mothers with HIV face a risk of infection, especially when breastfeeding. While current HIV prevention medicines exist, researchers want to find new options that are easier to use and work well in very young babies. This medication may offer a better choice for protecting infants in resource-limited settings.
You likely qualify if…
You likely don't qualify if…
Your baby will receive either a liquid or injectable form of the medication starting within the first 10 days of life. The study happens in stages: first, researchers test single and then repeated doses of the liquid form, then move to single and repeated doses of the injectable form. Throughout the study, your baby will have regular visits where doctors monitor health, check how the medication is being processed in the body, and perform blood tests to ensure safety.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
South Africa
Phase
Safety & dosing / Early efficacy
Sponsor
ViiV Healthcare
Enrollment target
~44 participants
Started
April 2026
Primary completion
October 2029
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
US GSK Clinical Trials Call Center
ViiV Healthcare
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.